Navigation Links
New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
Date:4/29/2009

d, randomized, parallel-group study conducted in 156 patients with early PD on stable dose of pramipexole immediate release:

  • Patients were randomized overnight to the pramipexole once-daily, extended release or to the pramipexole immediate release formulation (2:1 ratio). Primary efficacy endpoint was the proportion of patients successfully switched (no worsening of UPDRS II+III >15 percent from baseline and no drug-related adverse event leading to withdrawal). 95.5 percent of patients completed the trial, of which 84.5 percent were successfully switched (with or without dose adaptation) to the once-daily formulation. Mean pramipexole extended release dosage increased from 2.63 to 2.75mg/d (a ratio of 1:1.05) and mean pramipexole immediate release dosage from 2.74 to 2.83mg/d (a ratio of 1:1.03); these data support a 1:1 switch from pramipexole immediate release to pramipexole extended release.

In both studies, adverse events observed in patients receiving pramipexole extended release were similar to those seen in previous studies with immediate release pramipexole.

About Parkinson's disease

Parkinson's disease is a progressive neurological disorder that affects nearly one million people in the U.S. It is the second most common chronic neurological disorder in older adults after Alzheimer's. Every nine minutes someone is diagnosed with Parkinson's disease. Symptoms include tremor, muscle rigidity, slowed motion, shuffling gait, and a loss of facial expression. The symptoms vary from individual to individual, but become more severe over time. Although promising research is being conducted, there is currently no cure for Parkinson's disease.

About pramipexole

Pramipexole dihydrochloride tablets, in an immediate release formulation, are indicated in the U.S. for the treatment of the signs and symptoms of idiopathic Parki
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014  BioPontis Alliance for Rare Disease ... announced today the creation of a joint venture ... the rare disease known as Charcot- Marie-Tooth (CMT) ... model earlier this month. Today,s partnership announcement with ... model where researchers and all CMT dedicated organizations ...
(Date:10/19/2014)... 2014 Große Pharmafirmen werden ... Problem dabei ist, dass große Pharmafirmen nicht willens ... teilen. Es war deshalb nicht einfach, ... umso mehr, dass es uns gelungen ist! Wir ... aufzuschreiben - mit einem Vorbehalt - einige haben ...
(Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... and CEO of Curemark, LLC , ( www.curemark.com ), ... of neurological diseases, moderated the neuroscience roundtable focused on autism ... Hauppauge, New York.   Sponsored by the State ... and Cold Spring Harbor Laboratories, the Life Sciences Summit focused ...
... Oct. 11 BioStorage Technologies, a global leader ... storage for the pharmaceutical and biotechnology industries, has ... sample preparation services, including sample aliquoting and nucleic ... need for comprehensive sample management continues to grow, ...
Cached Medicine Technology:Curemark Moderates Autism Panel at Life Sciences Summit 2010 2Curemark Moderates Autism Panel at Life Sciences Summit 2010 3Industry Leader BioStorage Technologies Broadens Sample Management Operations to Include Laboratory Sample Preparation Services 2
(Date:10/20/2014)... October 20, 2014 It’s hard to imagine ... orphans and vulnerable children around the world, it’s a reality. ... people, many children are forced to walk barefoot on rocky ... families or play with their friends. , Buckner International's ... Air1 Radio in October to encourage support for ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury ... the greater Phoenix area and across Arizona reports record ... catastrophic automobile accidents. Statistics have indicated a steady increase ... As such, Hastings and Hastings has seen a steady ... who have been injured through no fault of their ...
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses ... long evening dresses . All the company’s old ... current discount is up to 66 percent off. ... the fashion field. Its dress specialists are striving to ... parts of the world. All the company’s items are ...
(Date:10/19/2014)... is a systemic disease that causes inflammation in ... affected members of the ancient Egyptian royal families. ... & Rheumatology , a journal of the American ... instead a degenerative spinal condition called diffuse idiopathic ... the 18th to early 20th Dynasties. , ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... A new study on old rats by a Penn State ... heart disease and aging in women. , Heart disease is ... of 75. After menopause, women lose their ability to produce ... somehow make women more vulnerable to heart disease and heart ...
... The Association of Schools of Public Health, the membership ... in North America, has developed a website with information ... to the H1N1 in communities around the country. ... schools and school spokespeople including instructions how to find ...
... insurer reports ... call volume CLEVELAND, May 4 Medical Mutual ... intensifying swine flu outbreak in the United States.In response, the company has posted a message on its ... and member groups to the Centers for Disease Control ...
... ( http://www.bullmarket.com ), an online investment ... subscribers with coverage of healthcare-related stocks, including Psych Solutions (Nasdaq: ... Aetna (NYSE: AET ), Covidien (NYSE: ... among others.All paid and trial subscribers to BullMarket.com can now ...
... May Help Arthritis Sufferers Manage Inflammation and Stiffness ... American adults currently suffer from arthritis - and as ... May has been deemed National Arthritis Month to ... manage associated symptoms. For many with arthritis, one step ...
... Hispanics and African-Americans are at a greater risk , ... to current estimates, more than 1 million cases of ... United States this year. While historically those most at risk ... red hair, light eyes, and generally older populations, dermatologists advise ...
Cached Medicine News:Health News:Penn State professor investigates estrogen, heart disease connection in women 2Health News:Schools of Public Health Launch Web Portal to Provide Local Media Resources on Response to H1N1 2Health News:Medical Mutual of Ohio Offers Swine Flu Assistance to Customers 2Health News:BullMarket.com Examines Healthcare Stocks: Psych Solutions, Cerner, Aetna, Covidien and HCP 2Health News:Experts Recommend Cherries For Pain Relief From Arthritis 2Health News:Experts Recommend Cherries For Pain Relief From Arthritis 3Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 2Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 3Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 4Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 5
... IgM Capture ELISA is for the qualitative ... recombinant antigens (WNRA) in serum as an ... West Nile virus infection in patients with ... must be confirmed by Plaque Reduction Neutralization ...
... Used for dilation of urethral ... of the bladder. The flare ... the catheter fits a standard ... is threaded to attach to ...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: